Vyvron Review: 13 Charges a Year, Not 12

Vyvron (vyvron.com) advertises weight-loss treatment "from $199/mo". Its own fine print says $199 per four weeks, billed every four weeks. Those are not the same product. Four-week billing means thirteen charges in a year, not twelve — $2,587 instead of $2,388, a $199 difference that appears nowhere on the page and is exactly the kind of thing this desk exists to find.

The unit is wrong, and the unit is the whole story

A calendar year holds just over thirteen four-week cycles, which means thirteen billings in a typical year rather than twelve. So a program billed every four weeks at $199 costs $2,587 over twelve months, while a program billed monthly at $199 costs $2,388. Vyvron's terms describe the four-week cycle correctly and its marketing describes it as "/mo". Both strings ship in the same bundle.¹

The extra $199 is not enormous on its own. It matters because it is invisible: nothing on the pricing card, nothing in the plan comparison, and nothing you would catch by reading the headline. If you are comparing Vyvron against a genuinely monthly program at the same sticker, the monthly one is $199 a year cheaper before either of you has done anything differently.

⛔ Tirzepatide cannot be bought by the month here

This is the finding that should decide it for most readers. Vyvron's weight-loss table has three tiers, and only the cheapest one is a recurring plan:

**Start** is $199 per four weeks, billed every four weeks, auto-renewing until cancelled. It is semaglutide only, and it is the only recurring rung on the board.

**Transform** displays "$285/mo" and actually charges **$790 once, for twelve weeks** of tirzepatide.

**Premium** displays "$248/mo" and actually charges **$2,981 once, for a full year** of tirzepatide.

There is no monthly tirzepatide plan. The smallest tirzepatide purchase Vyvron will sell you is $790 up front. We therefore file no month-to-month tirzepatide price for this provider at all, rather than substituting a prepay rung and calling it monthly — which is the substitution that puts unbuyable numbers on price boards across this category.

Look closely at that "$285/mo" and it gets worse. $790 across twelve weeks is $285 only if you divide by about 2.77 calendar months. Divide by three four-week cycles — the unit Vyvron itself bills in — and it is $263. The same table is using two different definitions of "per month" in adjacent rows. And if you actually stayed on Transform, four consecutive twelve-week blocks cover 48 weeks and cost $3,160, against $2,981 for the annual plan that covers 52.

Founding rates, and a progress bar that never moves

Vyvron currently sells "founding member" pricing: $199 per four weeks for weight loss, $149 for microdosing, $189 for longevity. The list rates it says apply when founding closes are $249, $179 and $229.¹ Individual longevity products are priced separately — injectable NAD+ and injectable sermorelin at $229, B12-MIC at $145.

Two things to know about the urgency. The homepage program cards and the program pages disagree: the cards say microdosing starts at $179 and longevity at $145, while the program pages say $149 and $189 per four weeks. We trust the program pages, because that is where the enrolment button and the billing disclosure live, and because the homepage's "$145" traces to the single cheapest longevity item rather than to the longevity program price. The homepage's microdosing figure is the post-founding list price displayed as though it were the current one.

And the counter reading "100 of 100 founding spots left" is a hardcoded constant behind a progress bar fixed at full width. It is not live and it will never decrement. That is not a price defect, but it tells you what kind of urgency you are being sold.

What is genuinely good here

Clinical services run through OpenLoop Health and its affiliated professional entities — a real, substantial telehealth infrastructure company, named in the privacy policy. That is the strongest thing about Vyvron.

The state disclosure is unusually specific and deserves credit: all 50 states plus DC, with a video visit required in Arkansas, DC, Delaware, Kansas, Mississippi, New Mexico, Rhode Island and West Virginia, and compounded GLP-1 unavailable in Mississippi. Most operators in this batch either claim 50 states with no caveats or, in two cases, never name a state at all.

The testimonial section ships placeholders saying patient stories are coming once founding members give written consent. That is honest, and it is also an unambiguous statement that this company has no track record yet.

What is missing

No pharmacy is named. No prescriber is named and no NPI is published. You are charged when you complete the intake — before a provider reviews it — with a full refund only if you cancel within 72 hours with no services rendered, or if a provider medically disqualifies you. Cancelling a recurring plan requires 72 hours' notice before the next billing date or you are charged for that cycle anyway. Prepaid Transform and Premium plans refund only the months whose medication has not shipped.

The corporate entity is Vyvron, LLC at 30 N Gould St in Sheridan, Wyoming — the most heavily used registered-agent mail-drop address in the country, and not an operating location.

The regulatory screen

The trading name and the named clinical partner both returned zero company-column matches in the FDA's live warning-letter index in August 2026.² The pass carried a positive control — a real February 2026 letter to an unrelated telehealth seller — which returned correctly, so the clean result is evidence and not a query that failed.

The verdict for a bargain hunter

If you want semaglutide and you go in knowing you will be charged thirteen times a year, $199 per four weeks is a fair rung and Vyvron is a defensible pick. If you want tirzepatide, this is not a monthly program and should not be compared as one — the entry cost is $790 and you should be pricing it against the tirzepatide board, where several programs sell a real monthly rate. It is a milder version of the problem at the seller whose every membership is a six-month non-cancelable contract: in both cases the monthly figure on the card is a division, not a rung. Auren Rx publishes an explicit no-commitment tirzepatide rung at $299, which is the structure Vyvron is missing. And whatever you decide, the general defence against unit games like this one is in how to choose a GLP-1 provider without overpaying and the teaser-rate trap; the evidence behind the medicines is in our research library.